Eisai Looks Outward As It Fortifies ‘Omics’ Analysis
Eisai has turned to external provider AWS to help power its "omics" research as part of a more biomarker-based approach to disease.
Scrip - August 5, 2026

BMS Likely Main APAC Beneficiary Of Any AstraZeneca Merger
The possible combination of AstraZeneca and Bristol Myers Squibb would create an APAC powerhouse - albeit one led by the UK party to the possible transaction.
Scrip - August 5, 2026

Amgen Readies Phase III Readouts To Offset Declines In I&I Portfolio
With Otezla sales falling after competing oral psoriasis drug launches and Enbrel continuing its slow decline, attention turns to Phase III dazodalibep in Sjogren’s disease and other programs.
Scrip - August 5, 2026

QMSR In Action: FDA’s Koven Warning Letter Flags Supplier Management And Design Change Failures
FDA cited Koven Technologies for marketing Doppler ultrasound devices for fetal use without required controls or risk assessment — one of the first enforcement actions under the new QMSR framework. Koven has attributed the labeling change to its contract manufacturer.
Medtech Insight - August 4, 2026

NTAP Alternative Pathway Gone, CJR-X Delayed: What FY2027 IPPS Means For Medtech
CMS finalized a 2.3% FY2027 inpatient payment rate increase and eliminated the alternative NTAP pathway for FDA breakthrough devices, while delaying the CJR-X joint replacement payment model to Jan. 1, 2028.
Medtech Insight - August 4, 2026

Global Medtech Guidance Tracker: July 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 90 documents have been posted on the tracker since its last update.
Medtech Insight - August 4, 2026

KKR’s $5.7Bn Integer Bid Reopens The Door For Private Equity In Medtech
KKR's $5.7bn take-private of Integer Holdings reflects a broader private equity push into medtech, with depressed valuations and non-cyclical revenue making device contract manufacturers an increasingly attractive target for financial sponsors.
Medtech Insight - August 4, 2026

Hemispheric Bets AI Can Give The Brain Its First Objective Test
Fresh out of stealth with $52m, the NeuroAI startup Hemispheric says its Descartes model can decode EEG into clinical insights.
Medtech Insight - August 4, 2026

Q&A With Sunscreen Developer On Formulating With BEMT
With the FDA's approval of bemotrizinol ushering in new sunscreen formulation possibilities for the US market, Solésence CEO Kevin Cureton shares his early takeaways on formulating with the first new approved UV filter in over two decades.
HBW Insight - August 4, 2026

P&G Puts Global Footprint On Personalized Supplement Sector With $3.8Bn Thorne Acquisition
Thorne, which for decades focused on practitioner sales following is 1984 launch, says P&G’s acquisition should boost “its mission to become the world's most trusted personalized health brand.”
HBW Insight - August 4, 2026

Could Blister Packs Finally Be Recycled at Scale?
Industry-led sustainable packaging collective CiPPPA has launched CircuBack, a UK take-back scheme designed to create a credible route for collecting and recycling empty blister packs from consumers.
HBW Insight - August 4, 2026

Over The Counter: Realizing Growth Through Pharmacy, With Simon-Kucher
In this episode of HBW Insight’s Over the Counter podcast, Simon-Kucher’s Christian Danelund and Chris Rebholz discuss the consultancy's Better Health Report and value of pharmacists to the consumer health industry.
HBW Insight - August 4, 2026

L’Oréal Outlines ‘Ambitious’ Gucci Beauty Plans
L'Oréal reported strong first-half results and laid out ambitious plans for its newly licensed Gucci beauty brand, with first products expected in 2028.
HBW Insight - August 4, 2026

Nicotine, Tobacco Researchers Suggest Doctors Recommend E-Cigarettes For Smoking Cessation
E-cigarettes “are less harmful than cigarettes and have been shown to be more effective for smoking cessation” than FDA-approved NRTs but “misperceptions of the harms of e-cigarettes are common among clinicians,” says Society for Research on Nicotine and Tobacco.
HBW Insight - August 4, 2026

Off-Patent, On Record: View Through The Journalist’s Lens With Generics Bulletin’s Dave Wallace
Generics Bulletin senior reporter Urt? Fultinavi?i?t? is joined by executive editor Dave Wallace for the inaugural episode of new interview podcast series “Off-Patent, On Record” to discuss how the generics and biosimilars industries have changed over the past decades.
Generics Bulletin - August 4, 2026

UK Hydrocortisone Appeal Loss Strengthens CMA Hand In Excessive Pricing Cases
The Court of Appeal upheld the CMA’s excessive-pricing and dominance findings against hydrocortisone suppliers, ruling that falling prices and new entry did not end the abuse, while sending the penalties back to the CAT for a fuller review.
Generics Bulletin - August 4, 2026

Will A Patent Cliff Spark The Biggest Merger Of All Time?
Bristol Myers Squibb’s looming patent cliff puts nearly 70% of its first-half revenues at risk, raising doubts over whether its pipeline can offset the decline of Eliquis, Opdivo and other major franchises.
Generics Bulletin - August 4, 2026

Lilly’s Opportunistic, Deal Type-Agnostic Approach To Business Development
Lilly’s business development chief Jake Van Naarden reviews the firm’s 31 deals so far in 2026 and the strategies and priorities underlying that activity.
In Vivo - August 4, 2026

Biotech Investors Are Waiting For The Wrong Milestone In AI Drug Discovery
Converge Bio's Dov Gertz says the value in AI drug discovery compounds at the platform layer, years before a candidate meets a regulator, and the milestones that reveal it can be measured now.
In Vivo - August 4, 2026